Randomized controlled study to examine physician use of pharmacogenetic information in patients receiving antiplatelet medication after percutaneous coronary intervention (PCI).
The study will randomize patients who have completed PCI and who are prescribed dual antiplatelet therapy to a genotype guided arm, in which CYP2C19 pharmacogenetic testing will be performed and a standard therapy arm without genetic testing. The study will examine the impact of pharmacogenetic testing on physician medication choice and clinical outcomes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
107
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States
Change in prescription of antiplatelet therapy
Number of individuals whose initial P2Y12 inhibitor therapy was changed to another P2Y12 inhibitor during time of follow up
Time frame: one year
Death, Myocardial Infarction, Stroke
Combined incidence of either death, myocardial infarction or stroke during follow up
Time frame: one year
Stent Thrombosis
Combined incidence of stent thrombosis according to Academic Research Consortium definitions during follow up
Time frame: one year
Urgent target vessel revascularization
Incidence of urgent target revascularization
Time frame: one year
Major and Minor Bleeding
Incidence of Major or Minor Bleeding according to GUSTO criteria during follow up
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.